Dr. Steven Quay on Newsmax TV

Dr. Stephen Quay, a scientist overseeing two COVID-19 trials, discusses the timeline for the U.S. returning to normalcy, noting positive trends in cases and deaths in New York. He highlights advancements in vaccine distribution, including Pfizer’s revelation that their vaccine no longer requires extreme cold storage and the potential effectiveness of just one dose. Quay explains that ongoing research and trials inform these developments, emphasizing the importance of understanding vaccine immunity and addressing compliance issues. Regarding concerns about vaccine variants and the need for multiple doses, Quay suggests that while variants are important to monitor, the current vaccines should provide substantial immunity against most variants, with potential need for periodic boosters akin to the annual flu shot due to COVID-19 likely becoming endemic.

For more information about Newsmax click here.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies